Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Outreach Efforts On E-Prescribing Urged

This article was originally published in The Pink Sheet Daily

Executive Summary

Outreach efforts are needed to improve public understanding of e-prescribing, the National Committee on Vital & Health Statistics Privacy & Confidentiality Subcommittee said at a Nov. 18 meeting

You may also be interested in...



Roche Begins Search For Partner On Pipeline Products

Roche will need partners for its pipeline products, Head of Research Strategy Paul Nakagaki, PhD, said

E-Prescribing Pilot Tests Should Address Patient Opt-Out, Cmte. Says

National Committee on Vital & Health Statistics' Privacy & Confidentiality Subcommittee will suggest to the HHS Secretary in a March 2005 letter that e-prescribing pilots test patient ability to opt-out, as well as interstate operability.

Roche Begins Search For Partner On Pipeline Products

Roche will need partners for its pipeline products, Head of Research Strategy Paul Nakagaki, PhD, said

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel